AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19783590 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SR)
Number of subjects: 0
Study 17223915 — intervention group
Group type: EXPERIMENTAL
Intervention: Karyotypic abnormalities
Number of subjects: 453
Study 17223915 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 1p abnormalities
Number of subjects: 453
Study 17223915 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 1q abnormalities
Number of subjects: 453
Study 17223915 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 13 abnormalities
Number of subjects: 453
Study 17223915 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex abnormalities
Number of subjects: 453
Study 17223915 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypodiploidy
Number of subjects: 453
Study 17223915 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 1p and/or 1q abnormalities
Number of subjects: 453
Study 17223915 — intervention group
Group type: EXPERIMENTAL
Intervention: Deletion of chromosome 13 or 13q
Number of subjects: 453
Study 15015148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (50 minutes of treadmill walking at 70% VO2max)
Number of subjects: 18
Study 15015148 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control trial)
Number of subjects: 18
Study 15015148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 18
Study 12113669 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermal dilute lipiodol embolization
Number of subjects: 131
Study 12113669 — intervention group
Group type: COMPARATOR
Intervention: Chemoembolization (lipiodol-epirubicin emulsion)
Number of subjects: 131
Study 9223883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine tape (3 X 5 cm, 18 mg of lidocaine) applied for 30 min, 60 min, and 120 min before venous cannulation
Number of subjects: 135
Study 9223883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine tape (3 X 5 cm, 18 mg of lidocaine) applied for 120 min
Number of subjects: 135
Study 9223883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine tape (3 X 5 cm, 18 mg of lidocaine)
Number of subjects: 135
Study 8462537 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nicomorphine
Number of subjects: 3
Study 8462537 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nicomorphine
Number of subjects: 3
Study 8462537 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nicomorphine
Number of subjects: 3
Study 8462537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicomorphine and its metabolites
Number of subjects: 3
Study 2829262 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 0
Study 2829262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol treatment
Number of subjects: 0
Study 2829262 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 30828929 — intervention group
Group type: EXPERIMENTAL
Intervention: BioChaperone glargine lispro co-formulation (BC Combo)
Number of subjects: 39
Study 28482406 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy (2-3 times)
Number of subjects: 97
Study 28482406 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment alone (Control)
Number of subjects: 97
Study 25557141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 39
Study 25557141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 25139116 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive systemic amoxicillin and metronidazole (AMX-MET) during non-surgical treatment
Number of subjects: 41
Study 25139116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 25139116 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive systemic amoxicillin and metronidazole (AMX-MET)
Number of subjects: 41
Study 22325128 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of depressive symptoms
Number of subjects: 5362
Study 22325128 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate levels of depressive symptoms
Number of subjects: 5362
Study 22325128 — intervention group
Group type: COMPARATOR
Intervention: Low levels of depressive symptoms
Number of subjects: 5362
Study 19185083 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0
Study 19185083 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 18094377 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus
Number of subjects: 1645
Study 18094377 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cyclosporine
Number of subjects: 1645
Study 18094377 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cyclosporine
Number of subjects: 1645
Study 18094377 — intervention group
Group type: COMPARATOR
Intervention: Low-dose sirolimus
Number of subjects: 1645
Study 15216449 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (MOX) 0.2 - 0.6 mg/d
Number of subjects: 200
Study 15216449 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (MET) 50 - 150 mg/d
Number of subjects: 200
Study 11791642 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AM, n = 40)
Number of subjects: 118
Study 11791642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NOR, n = 38)
Number of subjects: 118
Study 11791642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL, n = 40)
Number of subjects: 118
Study 9754991 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tolcapone (200 mg)
Number of subjects: 16
Study 9754991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tolcapone (50 mg)
Number of subjects: 16
Study 9754991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and intravenous tolcapone
Number of subjects: 16
Study 7871099 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cigarette after 1 hour deprivation
Number of subjects: 0
Study 7871099 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cigarette after 12 hours deprivation
Number of subjects: 0
Study 7871099 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking after 1 hour deprivation
Number of subjects: 0
Study 7871099 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking after 12 hours deprivation
Number of subjects: 0
Study 3066880 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation cephalosporin
Number of subjects: 0
Study 3066880 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation cephalosporin
Number of subjects: 0
Study 3066880 — intervention group
Group type: EXPERIMENTAL
Intervention: Early bone grafting
Number of subjects: 0
Study 3066880 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue coverage procedures
Number of subjects: 0
Study 1858666 — intervention group
Group type: EXPERIMENTAL
Intervention: Racal Airstream helmet respirator
Number of subjects: 19
Study 1858666 — intervention group
Group type: COMPARATOR
Intervention: 3M 9906 disposable mask
Number of subjects: 19
Study 137921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide via metered-dose inhaler
Number of subjects: 20
Study 137921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 137921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 20
Study 31082417 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg/day)
Number of subjects: 30
Study 31082417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28876367 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (1200 mg/day, orally)
Number of subjects: 100
Study 28876367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25877855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus FOLFIRI
Number of subjects: 1072
Study 25877855 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 1072
Study 23841259 — intervention group
Group type: EXPERIMENTAL
Intervention: YJQR combined endocrine therapy
Number of subjects: 44
Study 21911629 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive group (received explanations plus advice)
Number of subjects: 2944
Study 21911629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective group (received explanations)
Number of subjects: 2944
Study 21911629 — intervention group
Group type: COMPARATOR
Intervention: Control group (received no explanation)
Number of subjects: 2944
Study 19958861 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 0
Study 19958861 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16715347 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (training in HIV/AIDS, STI, and TB prevention over 3.5 days with supervisory follow-up)
Number of subjects: 233
Study 16715347 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control condition)
Number of subjects: 233
Study 15490272 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group (n=22)
Number of subjects: 52
Study 15490272 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=22)
Number of subjects: 52
Study 15490272 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 52
Study 15490272 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 11228592 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (plain and enteric-coated formulations)
Number of subjects: 12105
Study 11228592 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated formulations of aspirin
Number of subjects: 12105
Study 11228592 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin
Number of subjects: 12105
Study 11228592 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin with high-dose NSAIDs
Number of subjects: 12105
Study 11228592 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin with low-medium doses of NSAIDs
Number of subjects: 12105
Study 11228592 — intervention group
Group type: EXPERIMENTAL
Intervention: First two months of treatment with low-dose aspirin
Number of subjects: 12105
Study 9334096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric balloon implantation with a 1500 kcal diet (Group I)
Number of subjects: 40
Study 9334096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric balloon implantation with intensive additional therapy by a dietitian (Group II)
Number of subjects: 40
Study 9334096 — intervention group
Group type: COMPARATOR
Intervention: Sham implantation with intensive additional therapy by a dietitian (Group III)
Number of subjects: 40
Study 9334096 — intervention group
Group type: COMPARATOR
Intervention: Control group with diet advice only (Group IV)
Number of subjects: 40
Study 8487488 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 10 mg/kg body weight
Number of subjects: 16
Study 8487488 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 20 mg/kg body weight
Number of subjects: 16
Study 8487488 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 10 mg/kg and 20 mg/kg body weight
Number of subjects: 16
Study 3326114 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 5.0 mg
Number of subjects: 0
Study 3326114 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 0
Study 3326114 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 10.0 mg
Number of subjects: 0
Study 3326114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31876036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led distress screening intervention (NDTI)
Number of subjects: 194
Study 31876036 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 194
Study 31623132 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.556 W·s‐1 RAMP incremental test
Number of subjects: 20
Study 31623132 — intervention group
Group type: COMPARATOR
Intervention: 0.278 W·s‐1 RAMP incremental test
Number of subjects: 20
Study 28929950 — intervention group
Group type: EXPERIMENTAL
Intervention: High theoretical fidelity condition
Number of subjects: 56
Study 28929950 — intervention group
Group type: COMPARATOR
Intervention: Low theoretical fidelity condition
Number of subjects: 56
Study 26604649 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) therapy
Number of subjects: 231
Study 23182378 — intervention group
Group type: EXPERIMENTAL
Intervention: DreamLens (Hanita Lenses Investments, Hanita, Israel)
Number of subjects: 22
Study 23182378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinehart-Reeves (R&R; Danker Laboratories, Sarasota, FL)
Number of subjects: 22
Study 21199833 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 50 mg/day
Number of subjects: 118
Study 21199833 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 25 mg/day
Number of subjects: 118
Study 21199833 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 25 mg/day in CHF patients
Number of subjects: 118
Study 21199833 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 50 mg/day in CHF patients
Number of subjects: 118
Study 21199833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 21199833 — intervention group
Group type: COMPARATOR
Intervention: Placebo in CHF patients
Number of subjects: 118
Study 21199833 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan therapy
Number of subjects: 118
Study 18084782 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDF with cervical intervertebral fusion cage or Cloward procedure
Number of subjects: 95
Study 18084782 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term outcome data
Number of subjects: 95
Study 18084782 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Disability Index (NDI)
Number of subjects: 95
Study 17135984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (FLX and CBT)
Number of subjects: 0
Study 17135984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 0
Study 17135984 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 12374713 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (high concentration target)
Number of subjects: 12
Study 12374713 — intervention group
Group type: COMPARATOR
Intervention: Propofol (low concentration target)
Number of subjects: 12
Study 10434828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 100 micrograms kg‐1 min‐1
Number of subjects: 8
Study 10434828 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 8640147 — intervention group
Group type: EXPERIMENTAL
Intervention: Alutard SQ
Number of subjects: 37
Study 8640147 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 37
Study 2273519 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 146
Study 2273519 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 146
Study 2273519 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine and Methotrexate (MTX)
Number of subjects: 146
Study 2273519 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (Azathioprine or MTX)
Number of subjects: 146
Study 2273519 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (Adverse effect dropout)
Number of subjects: 146
Study 532919 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine hydrochloride 2%
Number of subjects: 24
Study 532919 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride 0.375%
Number of subjects: 24
Study 29370261 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 120
Study 29370261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26670938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 891
Study 23884322 — intervention group
Group type: EXPERIMENTAL
Intervention: Click City (®) : Tobacco program
Number of subjects: 2322
Study 23884322 — intervention group
Group type: COMPARATOR
Intervention: Usual Curriculum
Number of subjects: 2322
Study 22550837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg/Kg
Number of subjects: 40
Study 22550837 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0.5 microg/Kg
Number of subjects: 40
Study 22550837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 22550837 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 40
Study 20458909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear-acupuncture
Number of subjects: 90
Study 20458909 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp-acupuncture
Number of subjects: 90
Study 20458909 — intervention group
Group type: COMPARATOR
Intervention: Body-acupuncture
Number of subjects: 90
Study 17603143 — intervention group
Group type: EXPERIMENTAL
Intervention: Yamax Digiwalker step counts
Number of subjects: 129
Study 17603143 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer data for MVPA
Number of subjects: 129
Study 17603143 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily step count equating to 1-hr MVPA engagement
Number of subjects: 129
Study 16089149 — intervention group
Group type: EXPERIMENTAL
Intervention: Angong niuhuang pill (ANP)
Number of subjects: 97
Study 16089149 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 97
Study 12391947 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 460
Study 12391947 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 460
Study 10089851 — intervention group
Group type: EXPERIMENTAL
Intervention: EPS/ICD strategy
Number of subjects: 1200
Study 10089851 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy
Number of subjects: 1200
Study 7801868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (dose 1: 0.15 mg/kg bolus + 0.05 mg/kg/hour infusion)
Number of subjects: 193
Study 7801868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (dose 2: 0.3 mg/kg bolus + 0.1 mg/kg/hour infusion)
Number of subjects: 193
Study 7801868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (dose 3: 0.6 mg/kg bolus + 0.2 mg/kg/hour infusion)
Number of subjects: 193
Study 7801868 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5,000 U bolus + 1,000 U/hour infusion)
Number of subjects: 193
Study 7801868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (dose 1)
Number of subjects: 193
Study 7801868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (dose 2)
Number of subjects: 193
Study 7801868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (dose 3)
Number of subjects: 193
Study 2182703 — intervention group
Group type: EXPERIMENTAL
Intervention: Géméprost (vaginal suppository)
Number of subjects: 32
Study 2182703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulprostone (intravenous infusion)
Number of subjects: 32
Study 6154345 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with chemotherapy (bleomycin)
Number of subjects: 0
Study 6154345 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-phase treatment modality (bleomycin or BUdR combined with radiotherapy)
Number of subjects: 0
Study 31974133 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (295 patients)
Number of subjects: 587
Study 31974133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (292 patients)
Number of subjects: 587
Study 31046879 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 anti-waterpipe PSAs
Number of subjects: 45
Study 31046879 — intervention group
Group type: COMPARATOR
Intervention: 3 control videos
Number of subjects: 45
Study 28972236 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge individualized nutritional intervention (protein and energy enriched diet, oral nutritional supplements, vitamin D3/calcium supplement, telephone counseling by a dietitian)
Number of subjects: 210
Study 28972236 — intervention group
Group type: COMPARATOR
Intervention: Usual care regimen (control group)
Number of subjects: 210
Study 26370520 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 83
Study 26370520 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Mixtatin
Number of subjects: 83
Study 26370520 — intervention group
Group type: COMPARATOR
Intervention: 3Mix
Number of subjects: 83
Study 26370520 — intervention group
Group type: COMPARATOR
Intervention: simvastatin
Number of subjects: 83
Study 25128176 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated delivery drape
Number of subjects: 900
Study 25128176 — intervention group
Group type: COMPARATOR
Intervention: Indirect method (shallow bedpan)
Number of subjects: 900
Study 22459620 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein (PRO + CHO) beverage consumed immediately after exercise
Number of subjects: 0
Study 22459620 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO) beverage consumed immediately after exercise
Number of subjects: 0
Study 19675862 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% diatrizoate meglumine (Group 1, n=25)
Number of subjects: 61
Study 19675862 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% mannitol (Group 2, n=20)
Number of subjects: 61
Study 19675862 — intervention group
Group type: COMPARATOR
Intervention: Water (Group 3, n=16)
Number of subjects: 61
Study 17954941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mass media campaign
Number of subjects: 200
Study 17954941 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 200
Study 16078673 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 4 IU
Number of subjects: 40
Study 16078673 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 8 IU
Number of subjects: 40
Study 16078673 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 11912355 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost once daily
Number of subjects: 379
Study 11912355 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine twice daily
Number of subjects: 379